Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the cancer-immunotherapy desk.
health
A phase 2 trial in resectable non-small cell lung cancer found a major pathological response in 70.1% of patients who underwent surgery after perioperative ivonescimab plus chemotherapy. The study was noncomparative, and median event-free survival was not mature at the analysis cutoff.
health
In the single-arm MDT-BRIDGE phase 2 study, 142 people with resectable or borderline resectable non-small-cell lung cancer received durvalumab plus chemotherapy before multidisciplinary teams directed them to surgery or chemoradiotherapy. Surgery was performed in 74.6%; survival follow-up is still early.
health
A bioRxiv preprint uses spatial multi-omics and 3D imaging to map melanoma tumours treated with neoadjuvant immunotherapy. The study links organised immune structures, including tertiary lymphoid structures and germinal centres, with treatment response and disease-free survival.